Literature DB >> 11071299

Renal and cardiovascular actions of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids.

R J Roman1, K G Maier, C W Sun, D R Harder, M Alonso-Galicia.   

Abstract

1. Arachidonic acid (AA) is metabolized by cytochrome P450 (CYP)-dependent pathways to epoxyeicosatrienoic acids (EET) and 20-hydroxyeicosatetraenoic acid (20-HETE) in the kidney and the peripheral vasculature. 2. The present short review summarizes the renal and cardiovascular actions of these important mediators. 3. Epoxyeicosatrienoic acids are vasodilators produced by the endothelium that hyperpolarize vascular smooth muscle (VSM) cells by opening Ca2+-activated K+ (KCa) channels. 20-Hydroxyeicosatetraenoic acid is a vasoconstrictor that inhibits the opening of KCa channels in VSM cells. Cytochrome P450 4A inhibitors block the myogenic response of small arterioles to elevations in transmural pressure and autoregulation of renal and cerebral blood flow in vivo. Cytochrome P450 4A blockers also attenuate the vasoconstrictor response to elevations in tissue PO2, suggesting that this system may serve as a vascular oxygen sensor. Nitric oxide and carbon monoxide inhibit the formation of 20-HETE and a fall in 20-HETE levels contributes to the activation of KCa channels in VSM cells and the vasodilator response to these gaseous mediators. 20-Hydroxyeicosatetraenoic acid also mediates the inhibitory actions of peptide hormones on sodium transport in the kidney and the mitogenic effects of growth factors in VSM and mesangial cells. A deficiency in the renal production of 20-HETE is associated with the development of hypertension in Dahl salt-sensitive rats. 4. In summary, the available evidence indicates that CYP metabolites of AA play a central role in the regulation of renal, pulmonary and vascular function and that abnormalities in this system may contribute to the pathogenesis of cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11071299     DOI: 10.1046/j.1440-1681.2000.03349.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  29 in total

1.  Soluble epoxide hydrolase-dependent regulation of myogenic response and blood pressure.

Authors:  Dong Sun; Azita J Cuevas; Katherine Gotlinger; Sung Hee Hwang; Bruce D Hammock; Michal L Schwartzman; An Huang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-02-21       Impact factor: 4.733

2.  Mechanism of heme-heme oxygenase system impairment of endothelium contraction in the spontaneously hypertensive rat.

Authors:  Nader G Abraham; Attallah Kappas
Journal:  Hypertension       Date:  2011-09-26       Impact factor: 10.190

3.  Quantification of 20-hydroxyeicosatetraenoic acid by colorimetric competitive enzyme linked immunosorbent assay.

Authors:  Harry E Grates; Richard M McGowen; Smiti V Gupta; John R Falck; Thomas R Brown; Denis M Callewaert; Diane M Sasaki
Journal:  J Biosci       Date:  2003-02       Impact factor: 1.826

4.  Arachidonic acid ω-hydroxylase CYP4A11: inter-ethnic variations in the 8590T>C loss-of-function variant.

Authors:  Christian Lacks Lino Cardenas; Aurore Devos; Aminata Toure; Jaime Cardenas Garcia; Abderraouf Kenani; Florence Migot-Nabias; Franck Broly; Dany Chevalier
Journal:  Mol Biol Rep       Date:  2011-05-27       Impact factor: 2.316

5.  Unique mechanistic insights into the beneficial effects of soluble epoxide hydrolase inhibitors in the prevention of cardiac fibrosis.

Authors:  Padmini Sirish; Ning Li; Jun-Yan Liu; Kin Sing Stephen Lee; Sung Hee Hwang; Hong Qiu; Cuifen Zhao; Siu Mei Ma; Javier E López; Bruce D Hammock; Nipavan Chiamvimonvat
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-14       Impact factor: 11.205

6.  Expression of CYP4F2 in human liver and kidney: assessment using targeted peptide antibodies.

Authors:  Vandana Hirani; Anton Yarovoy; Anita Kozeska; Ronald P Magnusson; Jerome M Lasker
Journal:  Arch Biochem Biophys       Date:  2008-07-16       Impact factor: 4.013

7.  20-HETE and CYP4A2 ω-hydroxylase contribute to the elevated blood pressure in hyperandrogenemic female rats.

Authors:  Carolina Dalmasso; Rodrigo Maranon; Chetan Patil; Mohadetheh Moulana; Damian G Romero; Jane F Reckelhoff
Journal:  Am J Physiol Renal Physiol       Date:  2016-05-18

8.  Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches.

Authors:  Ning Li; Jun-Yan Liu; Valeriy Timofeyev; Hong Qiu; Sung Hee Hwang; Dipika Tuteja; Ling Lu; Jun Yang; Hideki Mochida; Reginald Low; Bruce D Hammock; Nipavan Chiamvimonvat
Journal:  J Mol Cell Cardiol       Date:  2009-08-28       Impact factor: 5.000

9.  Variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention.

Authors:  Silke Kullmann; Priska Binner; Kirsten Rackebrandt; Andreas Huge; Georg Haltern; Mark Lankisch; Reiner Füth; Eberhard von Hodenberg; Hans-Peter Bestehorn; Thomas Scheffold
Journal:  BMC Cardiovasc Disord       Date:  2009-10-08       Impact factor: 2.298

10.  Mechanisms of podocyte injury in diabetes: role of cytochrome P450 and NADPH oxidases.

Authors:  Assaad A Eid; Yves Gorin; Bridget M Fagg; Rita Maalouf; Jeffrey L Barnes; Karen Block; Hanna E Abboud
Journal:  Diabetes       Date:  2009-02-10       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.